ACN Accenture Plc Class A

Accenture to Transform Diabetic Patient Care Using Data-driven Analytics Platform

Accenture (NYSE: ACN) is collaborating with Roche (SIX: RO, ROG; OTCQX: RHHBY) to improve how diabetes care is managed and delivered through the development of a data-driven core analytics platform for Roche’s digital diabetes ecosystem. The platform and ecosystem will seamlessly connect patients, their caregivers and healthcare providers with a suite of new digital health services.

Under the terms of a five-year agreement, Roche’s new digital ecosystem and services will be built on the Accenture Intelligent Patient Platform, and offered to diabetes patients across North America, Europe and Asia. The open platform will provide Roche with the ability to gather and analyze data in a secure environment, generate new patient insights to provide more customized care, and easily collaborate and integrate with its ecosystem partners and devices used to manage diabetes care. The platform will integrate all existing and future products, solutions and services.

“This collaboration agreement with Accenture is an exciting step forward to offering truly integrated diabetes management solutions,” said Marcel Gmünder, Global Head of Roche Diabetes Care. “The open diabetes platform we are creating will enable us to analyze large amounts of data through algorithms and put them into context, respond faster to the needs of people with diabetes, caregivers and healthcare systems and personalize treatment which all-in-all can lead to improved outcomes. The collaboration builds on the trusted relationship we have had over the years. It will enable us to drive digital health in diabetes forward and offer integrated diabetes management solutions and services to shape the way care is being provided in the future, for improved therapy outcomes and more sustainable healthcare systems.”

Andrea Brückner, who leads Accenture’s Life Sciences practice in Europe, Africa, Middle East, and Latin America, said, “Uncontrolled diabetes can lead to serious health problems but also bring about substantial economic loss to those affected by the disease, through direct medical costs and loss of work and wages. We are collaborating with Roche to help combat this illness and increase the management of secondary health problems by working to change the standard of care and re-shaping the industry by seamlessly connecting patients, caregivers and healthcare providers to share information, data and insights to make better care decisions to deliver more precise, personalized support.”

This collaboration with Roche is driven by Accenture’s Intelligent Patient Services business, which is focused on enabling life sciences clients to deliver patient outcomes by bringing together strategic, analytic, and digital expertise to create differentiated solutions and services. Learn more about the Accenture Intelligent Patient Platform.

About Accenture

Accenture is a leading global professional services company, providing a broad range of services and solutions in strategy, consulting, digital, technology and operations. Combining unmatched experience and specialized skills across more than 40 industries and all business functions – underpinned by the world’s largest delivery network – Accenture works at the intersection of business and technology to help clients improve their performance and create sustainable value for their stakeholders. With more than 411,000 people serving clients in more than 120 countries, Accenture drives innovation to improve the way the world works and lives. Visit us at www.accenture.com.

EN
26/07/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Accenture Plc Class A

Accenture Plc: 3 directors

Three Directors at Accenture Plc sold 5,613 shares at between 242.386USD and 250.430USD. The significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...

Nicolas David ... (+2)
  • Nicolas David
  • Nicolas Thorez

ODDO : Shift to more favourable cycle to ease AI pressure on sector va...

While we do not deny the uncertainties and risks associated with artificial intelligence (pricing pressures, organisational change, etc.), we remain constructive on this issue, given the significant volume opportunities in prospect for the sector with the integration of agentic AI. Moreover, improving growth momentum in 2026 should reduce pressure on sector valuations (discount >30% vs Stoxx 600 vs a premium of 10% four years ago). On this basis, we have upgraded Bechtle (Outperform vs Neutral),...

Nicolas David ... (+2)
  • Nicolas David
  • Nicolas Thorez

ODDO : L’entrée dans un cycle plus favorable devrait réduire la pressi...

Sans nier les incertitudes et risques liés à l’IA (pressions tarifaires, changements organisationnels, etc.), nous restons constructifs sur cette thématique tant les opportunités de volumes autour de l’intégration de l’IA agentique sont importantes pour le secteur. D’autant plus que l’amélioration de la dynamique de croissance en 2026 devrait permettre de réduire la pression sur les valorisations du secteur (décote >30% vs Stoxx 600 contre une prime de 10% il y a 4 ans). Dans ce contexte, nous r...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch